Please ensure Javascript is enabled for purposes of website accessibility

Why TherapeuticsMD's Stock Jumped Today

By Brian Feroldi - Jan 21, 2020 at 1:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares pop after an SEC filing reveals that the biopharma has attracted the attention of a major financial institution.

What happened

Shares of TherapeuticsMD (TXMD 2.28%), a commercial-stage biopharma focused on women's health, rose 16% as of 12:50 p.m. EST on Tuesday. The bullish move is most likely linked to the news that financial giant JP Morgan (JPM -0.70%) has taken a substantial equity position in the company.

So what

An SEC filing revealed today that JP Morgan now owns 19.7 million shares of TherapeuticsMD's common stock. That represents more than 7% of shares outstanding.

Three traders pointing at a computer screen and smiling

Image source: Getty Images.

Traders are bidding up shares of this beaten-down stock in response to the vote of confidence from the financial giant.

Now what

TherapeuticsMD currently has three approved products on the market --Imvexxy, Bijuva, and Annovera -- and management believes they have nearly $2 billion in combined sales potential. However, ramping up a commercial team is expensive, so TherapeuticsMD is currently rapidly burning through capital as it works to build demand for its products. 

JP Morgan clearly believes in TherapeuticsMD's potential. Only time will tell if that bullish call was the right move. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TherapeuticsMD, Inc. Stock Quote
TherapeuticsMD, Inc.
$3.14 (2.28%) $0.07
JPMorgan Chase & Co. Stock Quote
JPMorgan Chase & Co.
$118.26 (-0.70%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.